In an environment of expiring patents, more stringent regulations and increased development costs, leading pharmaceutical and biotechnology companies are adopting new strategies that enable them to create more value for their customers. The traditional business strategy based solely on developing new molecules and blockbusters drugs cannot be sustained. The next challenge is to deliver complete therapeutic solutions that drive adherence, efficacy and safety for patients.
At Dassault Systèmes, we recognize the need for transformation in the industry and understand that pharmaceutical and biotech companies must adapt by engaging with patients early in development process and consistently post-market. Our 3DEXPERIENCE platform for the Life Sciences industry provides companies with solutions that help our clients create the most suitable product for the patient, through an end-to-end approach, and allows them to connect with patients, care givers and regulatory agencies both pre-market and post-market through an on-line experience platform helping to ensure efficacy, safety and quality of the drug.
Our Licensed to Cure for BioPharmasolution allows pharmaceutical and biotech companies to transition from its traditional product oriented model to the delivery of true therapeutic solutions with a flexible system that enables companies to be more reactive and respond more quickly to market needs and demands.